The drug from Xenoport (XNPT) is for moderate to severe Restless Leg Syndrome. This drug will compete with existing treatments IT is not clear if the drug presents an advantage compared to the existing treatments with the exception of a small number of patients.
It does not appear that the drug can generate enough profits to justify the jump in the stock price. For more details, see ZYX SHORT SELL CHANGE ALERTS
